Quick Answer
Immix Biopharma, Inc. reported Total Assets of $104.84 million for fiscal year 2025.
Immix Biopharma, Inc. Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2025 | $104.84M | +356.9% |
| 2024 | $22.95M | +15.2% |
| 2023 | $19.93M | +33.7% |
| 2022 | $14.91M | -18.1% |
| 2021 | $18.19M | +3271.4% |
| 2020 | $539.6K | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $20.08M | -20.1% | +28.4% |
| June 30, 2025 | $15.64M | -45.8% | -21.4% |
| March 31, 2025 | $19.89M | -42.1% | -13.3% |
| December 31, 2024 | $22.95M | +15.2% | -8.7% |
| September 30, 2024 | $25.14M | +11.9% | -12.8% |
| June 30, 2024 | $28.84M | +85.2% | -16.0% |
| March 31, 2024 | $34.35M | +160.0% | +72.4% |
| December 31, 2023 | $19.93M | +33.7% | -11.3% |
- Immix Biopharma, Inc. showed an increase of +356.9% in Total Assets compared to the prior fiscal year.
- Over the 2020–2025 period, Immix Biopharma, Inc.’s total assets has grown by 19329.4% (from $539.6 thousand to $104.84 million).
- The most recent figure is from Immix Biopharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: